• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

TABLE 57Total costs by health state (all costs in pound sterling)

InfliximabAdalimumab
State costsDrug costsTotal costsState costsDrug costsTotal costs
IND remission5205252052
IND relapse (severe disease)148958097298148910732562
IND relapse 2 (severe disease)148901489148901489
Transitional (severe disease)148901489148901489
IND relapse (moderate disease)4745809628347410731547
IND relapse 2 (moderate disease)47404744740474
Transitional (moderate disease)47404744740474
IND surgery459204592459204592
IND post-surgery remission7207272072
MNT remission52968102052715767
MNT relapse (severe disease)14893389487814897152204
MNT relapse 2 (severe disease)1489968245714897152204
Transitional (severe disease)148914522941148901489
MNT relapse (moderate disease)474338938634747151189
MNT relapse 2 (moderate disease)47496814424747151189
Transitional (moderate disease)474145219264740474
MNT surgery459204592459204592
MNT post-surgery remission72968104072715787

From: 4, Assessment of cost-effectiveness

Cover of A Systematic Review and Economic Evaluation of the Use of Tumour Necrosis Factor-Alpha (TNF-α) Inhibitors, Adalimumab and Infliximab, for Crohn's Disease
A Systematic Review and Economic Evaluation of the Use of Tumour Necrosis Factor-Alpha (TNF-α) Inhibitors, Adalimumab and Infliximab, for Crohn's Disease.
Health Technology Assessment, No. 15.6.
Dretzke J, Edlin R, Round J, et al.
© 2011, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.